Abstract:
BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed-up. RESULTS:A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients' DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis. CONCLUSIONS:Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Ydoi
10.1111/1759-7714.13238subject
Has Abstractpub_date
2020-01-01 00:00:00pages
8-14issue
1eissn
1759-7706issn
1759-7714journal_volume
11pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13175
更新日期:2019-10-01 00:00:00
abstract::A 78-year-old male with renal cell carcinoma was treated with combined immunotherapy of nivolumab and ipilimumab. After four courses of the treatment, a chest computed tomography (CT) revealed newly formed ground-glass opacities (GGOs) in both the lower lung lobes; drug-induced pneumonia was speculated. Eosinophil cou...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13848
更新日期:2021-01-21 00:00:00
abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12362
更新日期:2016-09-01 00:00:00
abstract::Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13466
更新日期:2020-07-01 00:00:00
abstract::Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13390
更新日期:2020-05-01 00:00:00
abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12846
更新日期:2018-11-01 00:00:00
abstract::A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuv...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13663
更新日期:2020-11-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12646
更新日期:2018-06-01 00:00:00
abstract::Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13312
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Radiofrequency ablation and microwave ablation are frequently prescribed for thoracic cancer. However, few writers have been able to draw on any systematic research into the differences between the two ablation methods. METHODS:A literature search was carried out using Embase, PUBMED, Web of Science, Cochra...
journal_title:Thoracic cancer
pub_type: 杂志文章,多中心研究
doi:10.1111/1759-7714.12973
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12407
更新日期:2017-01-01 00:00:00
abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12013
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12627
更新日期:2018-05-01 00:00:00
abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12277
更新日期:2015-11-01 00:00:00
abstract::Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13694
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12877
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12097
更新日期:2014-07-01 00:00:00
abstract:BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13366
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...
journal_title:Thoracic cancer
pub_type: 杂志文章,meta分析
doi:10.1111/1759-7714.12783
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND: The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS: The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00125.x
更新日期:2012-08-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13364
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lung cancer than in non-lung cancer patients. Moreover, the prevalence of DIC varies among the pathologic types of lung cancer. This study analyzed the relationship between coagulation factors and the pathologic t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12766
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13162
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:Central airway obstruction related to endobronchial malignancy is one of the most difficult oncological complications and requires efficient palliative intervention. METHODS:Fifty-three consecutive patients with unresectable endobronchial malignancy receiving bronchoscopic cryotherapy as palliative treatmen...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12248
更新日期:2015-11-01 00:00:00
abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13655
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. METH...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12154
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12499
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12925
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13308
更新日期:2020-03-01 00:00:00